logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Universitätsklinik für Innere Medizin III

Source: Site record.
https://salk.at/333.html

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Universitätsklinik für Innere Medizin III (University Clinic for Internal Medicine III) is a highly specialized medical, research, and teaching facility located at the Uniklinikum Salzburg - Campus LKH in Salzburg, Austria. Affiliated with the Paracelsus Medical Private University (PMU), the clinic is a premier center of excellence that focuses on hematology, medical oncology, hemostaseology, infectiology, and rheumatology. It plays an essential role in patient care, housing a dedicated Oncology Center and a specialized Cancer Research Laboratory that investigates tumor diversification, immunoevasion, and treatment resistance.

Business Status

Source: Google. OPEN

Business Category

Source: Google. Hospital department

Business Subcategory

Source: Google. Hospital department
Source: Trial-derived.
24Total Trials
Source: Trial-derived.
5Recruiting Trials
Source: Trial-derived.
5Active Trials
Source: Trial-derived.
0Completed Trials
Source: Trial-derived.
32Unique Conditions
Source: Trial-derived.
28Unique Sponsors

Conditions

Source: Trial-derived. Triple-Negative Breast Cancer (3)Source: Trial-derived. Acute Myeloid Leukemia (2)Source: Trial-derived. Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification (1)Source: Trial-derived. B-cell Non-Hodgkin Lymphoma (1)Source: Trial-derived. Breast Cancer (1)Source: Trial-derived. Breast Neoplasms (1)Source: Trial-derived. Chronic Myelomonocytic Leukemia (1)Source: Trial-derived. Colorectal Cancer (1)

Sponsors

Source: Trial-derived. Arbeitsgemeinschaft medikamentoese Tumortherapie (7)Source: Trial-derived. Merck KGaA, Darmstadt, Germany (4)Source: Trial-derived. EMD Serono Research & Development Institute, Inc. (3)Source: Trial-derived. Hoffmann-La Roche (3)Source: Trial-derived. Merck Sharp & Dohme LLC (2)Source: Trial-derived. Regeneron Pharmaceuticals (2)Source: Trial-derived. Alliance Foundation Trials, LLC. (1)Source: Trial-derived. Assign Data Management and Biostatistics GmbH (1)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Telehealth study visits

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. CT Scan
Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. PCR / molecular

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Intensity-modulated radiation therapy
Source: AI-inferred. Tumour tissue biopsy (guidance not stated)

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. PIK3CA mutation testing of tumour tissue
Source: AI-inferred. Tumour predictive biomarker testing